Companhia Siderúrgica Nacional (BVMF:CSNA3)
7.13
+0.58 (8.85%)
Jun 2, 2026, 5:05 PM GMT-3
Companhia Siderúrgica Nacional Employees
Companhia Siderúrgica Nacional had 29,000 employees as of December 31, 2025. The number of employees increased by 4,076 or 16.35% compared to the previous year.
Employees
29,000
Change
4,076
Growth
16.35%
Revenue / Employee
1.53M BRL
Profits / Employee
-68.92K BRL
Market Cap
9.46B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 29,000 | - | - |
| Dec 31, 2022 | 24,924 | 237 | 0.96% |
| Dec 31, 2021 | 24,687 | 1,491 | 6.43% |
| Jun 30, 2021 | 23,000 | - | - |
| Mar 31, 2021 | 23,000 | -1,869 | -7.52% |
| Dec 31, 2020 | 23,196 | -1,673 | -6.73% |
| Dec 31, 2019 | 24,869 | 1,170 | 4.94% |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Vale S.A. | 65,805 |
| Gerdau | 30,000 |
| Metalurgica Gerdau | 30,000 |
| Braskem | 8,233 |
| CSN Mineração | 7,796 |
| Unipar Carbocloro | 1,400 |
Companhia Siderúrgica Nacional News
- 18 days ago - National Steel Q1 Earnings Call Highlights - MarketBeat
- 18 days ago - National Steel Q1 Earnings Call Highlights - Nasdaq
- 19 days ago - Companhia Siderúrgica Nacional Earnings Call Transcript: Q1 2026 - Transcripts
- 19 days ago - Companhia Siderúrgica Nacional Earnings release: Q1 2026 - Filings
- 19 days ago - Companhia Siderúrgica Nacional Slides: Q1 2026 - Filings
- 19 days ago - Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting - GlobeNewsWire
- 26 days ago - TRexBio to Present Late-Breaking Data at the Society for Investigative Dermatology (SID) Annual Meeting Supporting TNFR2 Agonism as a Therapeutic Strategy for Atopic Dermatitis - Business Wire
- 4 weeks ago - Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting - GlobeNewsWire